Sparsentan Bests Irbesartan for Preserving Kidney Function in IgA Nephropathy
PHILADELPHIA — Sparsentan (Filspari) outperformed irbesartan in patients with IgA nephropathy over the 2-year phase III PROTECT trial. Over a 110-week treatment period, those on sparsentan had an average 42.8% (95% CI -49.8 to -35.0) reduction in urine protein-to-creatinine ratio compared with a 4.4% (95% CI −15.8 to 8.7%) reduction with irbesartan (geometric least-squares mean […]